Product Description
AMA0076 is a locally acting ROCK inhibitor that is able to induce altered cellular behavior of HTM cells.
Mechanisms of Action: ROCK Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amakem, NV
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glaucoma, Open-Angle|Hypertension
Phase 1: Hypertension|Glaucoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02003547 |
AMA0076-M-101 | P1 |
Completed |
Hypertension|Glaucoma |
2013-12-01 |
2019-03-20 |
Treatments |
|
NCT02136940 |
AMA0076-S-202 | P2 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2014-11-01 |
2019-03-20 |
Treatments |
|
NCT01693315 |
AMA0076-201 | P2 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2013-07-01 |
2019-03-19 |